Evonik stock faces BASF takeover hurdle as higher bid may not suffice
Published on 11/18/2026 at 12:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBASF bid meets resistance
- Evonik management continues to support the company as an independent business.
- Sources cited by Reuters say a higher BASF offer would need a compelling industrial rationale.
- Investors are awaiting BASF's next move in the potential transaction.
On Wednesday, November 18, 2026, Reuters reported that a higher BASF offer on paper would not by itself be enough to secure a takeover of Evonik. Two sources close to Evonik said the proposal would need to present a compelling industrial rationale for the deal.
Reuters also cited an internal memo in which Evonik's management told employees that it remained convinced the company had a strong future as an independent business. The message keeps the strategic focus on Evonik's standalone plan while BASF weighs how to build support for a potential transaction.
Industrial rationale remains decisive
The report follows coverage by Handelsblatt, which said BASF might need to raise its offer materially to overcome resistance. A bid of 26 to 28 euros per share was cited as a level that could help break the deadlock. Reuters said Evonik and BASF declined to comment on that report.
For investors, the central issue is therefore broader than the headline price. A renewed approach would need to address Evonik's strategic independence, the industrial logic of combining the two German chemicals groups and the interests of employees and other stakeholders. The wording from Evonik's management signals that a financial premium alone may not settle those questions.
Evonik's portfolio of specialty chemicals businesses gives the potential transaction strategic significance for both companies. BASF could seek scale and portfolio benefits, while Evonik's management is emphasizing the value of executing its own strategy. The competing positions leave the timing and terms of any further approach important variables for the stock.
Evonik stock traded at 22.42 euros on Lang & Schwarz at 12:01 CET on Wednesday, November 18, 2026, 1.54 percent above the Xetra close of Tuesday, November 17.
Investors await BASF's next step
The next market-moving development would be a formal BASF proposal, a clearer strategic case or a fresh statement from Evonik. Until then, the shares remain sensitive to reports about the possible transaction as well as to the company's underlying earnings outlook.
German equities, including the DAX, provide the broader market setting for Evonik stock.
Further coverage is available in More news and analyses on Evonik stock.
Evonik Industries AG
- ISIN: DE000EVNK013
- Xetra symbol: EVK.DE
- Lang & Schwarz quote: 22.42 euros on Wednesday, November 18, 2026, at 12:01 CET
- Change versus Xetra close: 1.54 percent above the 22.08-euro close of Tuesday, November 17, 2026
